SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.

doi:10.1038/s41467-021-21609-2

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.

Nature communications - 11 Mar 2021

Bertoglio Federico, Meier Doris, Langreder Nora, Steinke Stephan, Rand Ulfert, Simonelli Luca, Heine Philip Alexander, Ballmann Rico, Schneider Kai-Thomas, Roth Kristian Daniel Ralph, Ruschig Maximilian, Riese Peggy, Eschke Kathrin, Kim Yeonsu, Schäckermann Dorina, Pedotti Mattia, Kuhn Philipp, Zock-Emmenthal Susanne, Wöhrle Johannes, Kilb Normann, Herz Tobias, Becker Marlies, Grasshoff Martina, Wenzel Esther Veronika, Russo Giulio, Kröger Andrea, Brunotte Linda, Ludwig Stephan, Fühner Viola, Krämer Stefan Daniel, Dübel Stefan, Varani Luca, Roth Günter, Čičin-Šain Luka, Schubert Maren, Hust Michael

Abstract excerpt

COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry, recognizing it with the receptor binding domain (RBD) of the S1 subunit of the viral spike protein. We present the use of phage display to select anti-SARS-CoV-2 spike antibodies from the human naïve antibody gene libraries HAL9/10 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibodies, Neutralizing

Share to Antibody Affinity

Share to Healthy Volunteers

Share to Host Microbial Interactions

Share to Neutralization Tests

Share to Pandemics

Share to Peptide Library

Source

Open in PubMed Open full text

Identifiers

PMID: 33707427
DOI: 10.1038/s41467-021-21609-2
PMCID: PMC7952403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.PMID 33707427Read ↗

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity Read ↗

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read ↗

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity Read ↗

Fully human single-domain antibodies against SARS-CoV-2Semantic proximity Read ↗

Synthetic repertoires derived from convalescent COVID-19 patients enable discovery of SARS-CoV-2 neutralizing antibodies and a novel quaternary binding modalitySemantic proximity Read ↗

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutationsSemantic proximity Read ↗

Potent SARS-CoV-2 neutralizing antibodies selected from a human antibody library constructed decades agoSemantic proximity Read ↗

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD MutationsSemantic proximity Read ↗

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity Read ↗

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read ↗

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies.Semantic proximity Read ↗

A humanized nanobody phage display library yields potent binders of SARS CoV-2 spikeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.